Replies to post #90856 on Biotech Values

[DewDiligence]

FDA approves MRK’s Asamanex+Foradil combination for asthma:

http://www.reuters.com/article/idCNLDE65N0S320100624

The new product, called Dulera, will compete with GSK’s Advair and AZN’s Symbicort, which are also combinations of a corticosteroid and a LABA. However, Dulera’s approval may have come too late to accomplish much for MRK insofar as LABA’s are now considered unduly risky for the majority of asthma patients.